1. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». IV издание. М., 2012. 
2. Chuchalin A, Khaltaev N, Antonov N et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD 2014; 9: 963–74.
3. GINA 2015. ginasthma.org
4. Reddel H, Ware S, Marks G et al. Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353: 364–9.
5. Sigurs N, Gustafsson PM, Bjarnason R et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005; 171 (2): 137–41.
6. Sigurs N, Aljassim F, Kjellman B et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010; 65 (12): 1045–52.
7. Teichtahl H, Buckmaster N, Pertnikovs E. The incidence of respiratory tract infection in adults requiring hospitalization for asthma. Chest 1997; 112: 591–6.
8. Atmar RL, Guy E, Guntupalli KK et al. Respiratory tract viral infections in inner-city asthmatic adults. Arch Intern Med 1998; 158: 2453–9.
9. Дзюблик А.Я., Симонов С.С., Ячник В.А. Клиническая эффективность и безопасность противовирусного препарата Ингавирин в комплексном лечении больных с обострением бронхиальной астмы, ассоциированным с ОРВИ. Пульмонология. 2013; 6: 43–50.
10. Message SD, Laza-Stanca V, Mallia P et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A 2008; 105: 13562–7.
11. Bui RH, Molinaro GA, Kettering JD et al. Virus-specific IgE and IgG4 antibodies in serum of children infected with respiratory syncytial virus. J Pediatr 1987; 110: 87–90.
12. Rabatic S, Gagro A, Lokar-Kolbas R et al. Increase in CD23+ B cells in infants with bronchiolitis is accompanied by appearance of IgE and IgG4 antibodies specific for respiratory syncytial virus. J Infect Dis 1997; 175: 32–7.
13. Cheung DS, Ehlenbach SJ, Kitchens RT et al. Cutting edge: CD49d+ neutrophils induce FcepsilonRI expression on lung dendritic cells in a mouse model of postviral asthma. J Immunol. 2010; 185: 4983–7.
14. Stephens R, Randolph DA, Huang G et al. Antigen-nonspecific recruitment of Th2 cells to the lung as a mechanism for viral infection-induced allergic asthma. J Immunol 2002; 169: 5458–67.
15. Cheung DS, Ehlenbach SJ, Kitchens T et al. Development of atopy by severe paramyxoviral infection in a mouse model. Ann Allergy Asthma Immunol 2010; 105: 437–43.
16. Cheung DS, Grayson MH. Role of Viruses in the Development of Atopic Disease in Pediatric Patients. Curr Allergy Asthma Rep 2012. DOI 10.1007/s11882-012-0295-y
17. Al-Garawi AA, Fattouh R, Walker TD et al. Acute, but not resolved, influenza A infection enhances susceptibility to house dust mite-induced allergic disease. J Immunol 2009; 182: 3095–104.
18. Durrani SR, Montville DJ, Pratt AS et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol 2012; 130: 489–95.
19. Holtzman MJ. Asthma as a chronic disease of the innate and adaptive immune systems responding to viruses and allergens. J Clin Invest 2012; 122 (8): 2741–8.
20. Gavala ML, Bertics PJ, Gern JE. Rhinoviruses, allegic inflammation and asthma. Immunol Rev 2011; 242 (1): 69–90.
21. Wark PA, Johnston SL, Bucchieri F et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005; 201 (6): 937–47.
22. Contoli M, Message SD, Laza-Stanca V et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006; 12 (9): 1023–6.
23. Lopez-Souza N, Favoreto S, Wong H et al. In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects. J Allergy Clin Immunol 2009; 123 (6): 1384–90: e2.
24. Schwantes E, Denlinger L, Evans M et al. Severity of virus-induced asthma symptoms is inversely related to resolution IFN-l expression. J Allergy Clin Immunol 2015; 135 (6): 1656–9.
25. Shadman KA, Wald ER. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin Biol Ther 2011; 11 (11): 1455–67.
26. Simoes EA, Groothuis JR, Carbonell-Estrany X et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007; 151: 34–42. 42 e31.
27. Suissa S, Ernst P, Benayoun S et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332–6.
28. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392–7.
29. Prazma C, Kral K, Gul N et al. Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections. Respir Med 2010; 104: 780–7.
30. Wark PA, Grissell T, Davies B et al. Diversity in the bronchial epithelial cell response to infection with different rhinovirus strains. Respirology 2009; 14: 180–6.
31. Calvo C, Garcia ML, Pozo F et al. Role of rhinovirus C in apparently life-threatening events in infants, Spain. Emerg Infect Dis 2009; 15: 1506–8.
32. Çalișkan M, Bochkov Y, Kreiner-Møller E et al. Rhinovirus Wheezing Illness and Genetic Risk of Childhood-Onset Asthma. N Engl J Med 2013; 368: 1398–407.
33. Van Ly D, King NJ, Moir LM et al. Effects of b2 agonists, corticosteroids, and novel therapies on rhinovirus-induced cytokine release and rhinovirus replication in primary airway fibroblasts. J Allergy 2011; 2011: 457169.
34. Tacon CE, Newton R, Proud D et al. Rhinovirus-induced MMP-9 expression is dependent on Fra-1, which is modulated by formoterol and dexamethasone. J Immunol 2012; 188: 4621–30.
35. Van Ly D, Faiz A, Jenkins C et al. Characterising the mechanism of airway smooth muscle b2 adrenoceptor desensitization by rhinovirus infected bronchial epithelial cells. PLoS One 2013; 8: e56058.
36. Oliver B, Robinson P, Peters M, Black J. Viral infections and asthma:an inflammatory interface? Eur Respir J 2014; 44: 1666–81.
37. Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med 2007; 357: 1841–54.
38. Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005; 127: 1312–26.
39. Hallstrand TS, Henderson WR Jr. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol 2010; 10: 60–6.
40. Mehrotra AK, Henderson WR Jr. The role of leukotrienes in airway remodeling. Curr Mol Med 2009; 9: 383–91.
41. McCarthy M, Weinberg J. Eicosanoids and Respiratory Viral Infection: Coordinators of Inflammation and Potential Therapeutic Targets. Mediat Inflamm 2012, Article ID 236345.
42. Seymour ML, Gilby N, Bardin PG et al. Rhinovirus infection increases 5-lipoxygenase and cyclooxygenase-2 in bronchial biopsy specimens from nonatopic subjects. J Infect Dis 2002; 185: 540–4.
43. Gentile DA, Fireman P, Skoner DP. Elevations of local leukotriene C4 levels during viral upper respiratory tract infections. Ann Allergy Asthma Immunol 2003; 91: 270–4.
44. Matsuse H, Hirose H, Tsuchida T et al. Effects of respiratory syncytial virus infection on dendritic cells and cysteinyl leukotrienes in lung tissues of a murine model of asthma. Allergol Int 2007; 56: 165–9.
45. van Schaik SM, Tristram DA, Nagpal IS et al. Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol 1999; 103: 630–6.
46. Matsuse H, Fukahori S, Tsuchida T et al. Effects of a short course of pranlukast combined with systemic corticosteroid on acute asthma exacerbation induced by upper respiratory tract infection. J Asthma 2012; 49 (6): 637–41.
47. Matsuse H, Tsuchida T, Fukahori S et al. Retrospective cohort study of leukotriene receptor antagonist therapy for preventing upper respiratory infection-induced acute asthma exacerbations. Allergy Rhinol 2013; 4: 127–31.
48. Venarske DL, Busse WW, Griffin MR et al. The relationship of rhinovirus-associated asthma hospitalizations with inhaled corticosteroidsand smoking. J Infect Dis 2006; 193: 1536–43.

Н.М.Ненашева

ФГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России